---
title: Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200
  therapeutic antibodies for the treatment of acute myeloid leukemia
date: '2023-10-23'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37872381/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20231024180821&v=2.17.9.post6+86293ac
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Despite recent advances in the treatment of acute myeloid leukemia (AML),
  there has been limited success in targeting surface antigens in AML, in part due
  to shared expression across malignant and normal cells. Here, high-density immunophenotyping
  of AML coupled with proteogenomics identified unique expression of a variety of
  antigens, including the RNA helicase U5 snRNP200, on the surface of AML cells but
  not on normal hematopoietic precursors and skewed Fc receptor distribution in the
  ...
disable_comments: true
---
Despite recent advances in the treatment of acute myeloid leukemia (AML), there has been limited success in targeting surface antigens in AML, in part due to shared expression across malignant and normal cells. Here, high-density immunophenotyping of AML coupled with proteogenomics identified unique expression of a variety of antigens, including the RNA helicase U5 snRNP200, on the surface of AML cells but not on normal hematopoietic precursors and skewed Fc receptor distribution in the ...